Valuation Novartis AG Xetra

Stocks

Real-time Estimate Tradegate 07:18:01 2026-09-14 EDT			5-day change	1st Jan Change
122.01 ^EUR	+2.91%		-13.94%	+0.27%

09-11	Scholar Rock gets first FDA nod for rare muscle-wasting disease (September 11)	RE
09-11	US FDA approves Scholar Rock's muscle weakness drug	RE

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	196,458	194,448	207,167	195,514	266,003	261,033	-	-
Change	-	-1.02%	6.54%	-5.62%	36.05%	-1.87%	-	-
Enterprise Value (EV) ¹	204,649	203,482	219,178	213,458	289,870	292,618	288,929	281,913
Change	-	-0.57%	7.71%	-2.61%	35.8%	0.95%	-1.26%	-2.43%
P/E	8.2x	28.3x	14.1x	16.5x	19.2x	19.4x	16.3x	14.2x
PBR	2.9x	3.23x	4.41x	4.52x	5.73x	5.51x	5.11x	4.58x
PEG	-	-0.4x	0x	-1x	0.9x	-10.46x	0.9x	0.9x
Capitalization / Revenue	3.81x	3.85x	4.44x	3.78x	4.69x	4.53x	4.26x	4x
EV / Revenue	3.96x	4.03x	4.7x	4.13x	5.11x	5.08x	4.71x	4.32x
EV / EBITDA	11.2x	10.9x	12.2x	10.2x	12.4x	12.6x	11.5x	10.4x
EV / EBIT	12.3x	12.2x	13.4x	10.9x	13.2x	13.4x	12.2x	11x
EV / FCF	15.4x	17x	16.6x	13.1x	16.5x	19x	17.1x	14.6x
FCF Yield	6.49%	5.87%	6.01%	7.61%	6.07%	5.26%	5.85%	6.86%
Dividend per Share ²	3.36	3.5	3.823	3.856	-	4.407	4.599	4.783
Rate of return	3.83%	3.87%	3.79%	3.94%	-	3.21%	3.35%	3.48%
EPS ²	10.71	3.19	7.15	5.92	7.21	7.076	8.401	9.67
Distribution rate	31.4%	110%	53.5%	65.1%	-	62.3%	54.7%	49.5%
Net sales ¹	51,626	50,545	46,660	51,722	56,674	57,640	61,315	65,287
EBITDA ¹	18,246	18,613	17,937	21,006	23,415	23,235	25,213	27,216
EBIT ¹	16,588	16,665	16,372	19,494	21,889	21,800	23,628	25,569
Net income ¹	24,021	6,955	14,854	11,939	13,967	14,190	15,746	17,587
Net Debt ¹	8,191	9,034	12,011	17,944	23,867	31,584	27,896	20,880
Reference price ²	87.82	90.40	100.79	97.79	138.63	137.33	137.33	137.33
Nbr of stocks (in thousands)	2,237,092	2,150,980	2,055,460	1,999,270	1,918,792	1,900,715	-	-
Announcement Date	2/2/22	2/1/23	1/31/24	1/31/25	2/4/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	31.77x	11.54x	23.41x	0.62%	994B
JOHNSON & JOHNSON	29.54x	-	-	2.02%	640B
ABBVIE INC.	32.92x	7.63x	15.78x	2.67%	454B
ROCHE HOLDING AG	18.71x	4.57x	11.31x	2.91%	337B
NOVARTIS AG	19.41x	5.08x	12.59x	3.21%	261B
ASTRAZENECA PLC	20.34x	4.19x	11.96x	2.11%	246B
AMGEN INC.	23.87x	6.3x	11.23x	2.67%	204B
NOVO NORDISK A/S	12.3x	4.48x	9.37x	4.08%	190B
GILEAD SCIENCES, INC.	-43.47x	6.35x	24.81x	2.29%	178B
Average	16.16x	6.27x	15.06x	2.51%	389.42B
Weighted average by Cap.	23.19x	7.72x	17.10x	2.05%